MRVI Stock — Maravai Lifesciences Holdings Inc

Maravai Lifesciences Holdings Inc (MRVI)

Updated October 16, 2026.

MRVI is a Stock. Total return is -77.3% over the past 5.9 years, 210.2 points behind SPY at 132.9%.

Maravai LifeSciences is a life sciences company that manufactures and sells products enabling the development of drug therapies, vaccines, cell and gene therapies, and diagnostics globally. Operating through two segments—TRILINK, which produces reagents and components for nucleic acid synthesis and modification, and CYGNUS, which provides analytical products and services for biopharmaceutical manufacturing—the company serves biopharmaceutical firms, research institutions, and diagnostics companies. The company does not currently have an established distribution schedule.

MRVI performance versus SPY

Price and return data through 2026-10-16.

Total return is -77.3% over the past 5.9 years, 210.2 points behind SPY at 132.9%. Over the past year its total return — price change plus distributions reinvested — is 94.6%. Its deepest 1-year drawdown was 29.6%.

MRVI key facts

Asset type

Stock

Asset class

Equity

Inception date

11/20/2020

Distribution frequency

None

Last close

$6.79 (as of 2026-10-16)

Market cap

$1,011,639,011

Average volume

2215098.0

Beta

0.544

Payout ratio

0.0%

Forward P/E

370.3704

EPS

$-0.56

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MRVI risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 29.6%.

Who may consider MRVI — and who may not

It is a weaker fit for investors who need monthly cash flow (MRVI does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MRVI

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions